| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5581737 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 13 Pages |
Abstract
The QOL among patients receiving nilotinib administered as second-line therapy was very good and adherence to the treatment was high. The efficacy and safety of the drug were confirmed in the real-life setting.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Tomasz Sacha, Joanna Góra-Tybor, Ewa WÄ
sak-Szulkowska, SÅawomira Kyrcz-KrzemieÅ, Ewa MÄdraÅ, RafaÅ Becht, Grażyna Bober, Aneta Kotowska, Joanna WÄ
cÅaw, Andrzej Hellmann,